Ser293
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser293  -  PDHA1 (human)

Site Information
TYRyHGHsMsDPGVs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448258
Available spectra:  4 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 4 , 25 ) , immunoprecipitation ( 11 , 36 ) , mass spectrometry ( 6 , 7 , 8 , 11 , 13 , 15 , 20 , 21 , 23 , 24 , 29 , 32 , 33 , 34 , 36 , 37 , 38 , 40 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 52 , 53 , 56 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 307 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 328 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 346 , 347 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 356 , 357 , 358 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 420 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 438 , 439 , 440 , 441 , 442 , 443 , 444 , 445 , 446 , 447 , 448 , 449 , 450 , 451 , 452 , 453 , 454 , 455 , 456 , 457 , 458 , 459 , 460 , 461 , 462 , 463 , 464 , 465 , 466 , 467 , 468 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 , 554 , 555 , 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 , 568 , 569 , 570 , 571 , 572 , 573 , 574 , 575 , 576 , 577 , 578 , 579 , 580 , 581 , 582 , 583 , 584 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 592 , 593 , 594 , 595 , 596 , 597 , 598 , 599 , 600 , 601 , 602 , 603 , 604 , 605 , 606 , 608 , 609 , 610 , 611 , 612 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 636 , 637 , 638 , 639 , 640 , 641 , 642 , 643 , 645 , 646 , 647 , 648 , 649 , 650 , 651 , 652 , 653 , 654 , 655 , 656 , 657 , 658 , 659 , 660 , 661 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 , 710 , 715 ) , mutation of modification site ( 11 , 19 , 36 ) , phospho-antibody ( 1 , 2 , 3 , 5 , 9 , 10 , 11 , 12 , 14 , 16 , 17 , 18 , 19 , 22 , 25 , 27 , 30 , 35 , 36 , 39 , 41 , 55 , 57 , 75 , 90 , 607 , 708 ) , phosphoamino acid analysis ( 11 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 9 , 10 , 11 , 12 , 14 , 16 , 17 , 18 , 19 , 22 , 25 , 27 , 30 , 35 , 36 , 39 , 41 , 55 , 57 , 75 , 90 , 607 , 708 )
Disease tissue studied:
atrial fibrillation ( 576 ) , bone cancer ( 636 , 637 ) , osteosarcoma ( 636 , 637 ) , brain cancer ( 11 , 19 , 41 , 646 ) , glioblastoma ( 11 , 19 ) , glioblastoma multiforme ( 646 ) , glioma ( 11 , 19 , 41 , 646 ) , breast cancer ( 4 , 10 , 13 , 32 , 33 , 61 , 298 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 567 , 568 , 569 , 577 , 578 , 581 , 582 , 583 , 608 , 609 , 624 , 641 ) , breast adenocarcinoma ( 4 ) , breast ductal carcinoma ( 32 ) , HER2 positive breast cancer ( 8 ) , luminal A breast cancer ( 8 ) , luminal B breast cancer ( 8 ) , breast cancer, surrounding tissue ( 8 , 298 , 582 ) , breast cancer, triple negative ( 8 , 10 , 32 ) , cervical cancer ( 192 ) , cervical adenocarcinoma ( 192 ) , colorectal cancer ( 1 , 17 , 549 , 554 , 611 , 612 ) , colorectal carcinoma ( 1 , 17 , 611 , 612 ) , colorectal cancer, surrounding tissue ( 126 , 127 , 129 , 155 , 416 , 418 , 420 , 421 , 441 , 442 , 444 , 445 , 551 , 552 , 553 ) , esophageal cancer ( 364 , 366 , 367 , 375 , 376 , 377 , 379 , 380 , 381 , 384 , 388 , 389 , 390 , 392 , 395 , 396 , 401 , 404 , 405 , 407 , 408 , 410 ) , esophageal cancer, surrounding tissue ( 363 , 365 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 378 , 382 , 383 , 385 , 386 , 387 , 393 , 394 , 397 , 398 , 399 , 400 , 402 , 403 , 406 , 409 , 411 , 412 ) , gastric cancer ( 69 , 181 , 182 , 253 , 255 , 257 , 258 , 268 , 269 , 272 , 273 , 275 , 276 , 277 , 278 , 279 , 282 , 285 , 286 , 480 , 482 , 484 , 485 , 488 , 490 , 491 , 492 , 493 , 497 , 498 , 500 , 501 , 503 , 505 , 506 , 509 , 510 , 511 , 572 , 573 , 587 , 589 , 590 , 591 , 598 , 600 ) , gastric carcinoma ( 253 , 255 , 257 , 258 , 480 , 482 , 484 , 485 , 488 , 490 , 491 , 492 , 493 , 497 , 498 , 572 , 573 , 590 , 591 ) , gastric carcinoma, surrounding tissue ( 271 , 274 , 280 , 281 , 283 , 284 , 287 , 479 , 481 , 483 , 486 , 487 , 489 , 494 , 495 , 496 , 499 , 502 , 504 , 507 , 508 , 512 , 585 , 586 , 588 , 594 , 599 , 601 ) , HNSCC ( 14 ) , kidney cancer ( 299 , 304 , 307 ) , leukemia ( 70 , 72 , 73 , 74 , 75 , 76 , 83 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 142 , 143 , 144 , 145 , 153 , 154 , 165 , 166 , 167 , 168 , 172 , 173 , 174 , 175 , 177 , 178 , 179 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 248 , 249 , 250 , 251 , 252 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 301 , 302 , 303 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 361 , 362 , 448 , 449 , 450 , 451 , 454 , 455 , 556 , 557 , 565 , 566 , 571 , 574 , 592 , 596 , 597 , 604 , 605 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632 , 633 , 634 , 635 , 638 , 639 , 640 , 642 , 643 , 650 , 651 , 652 , 653 , 655 , 656 , 657 , 658 , 659 , 660 , 662 , 663 , 664 , 665 , 666 , 667 , 668 , 669 , 670 , 671 , 672 , 673 ) , acute myelogenous leukemia ( 70 , 642 , 643 , 655 , 656 , 657 , 658 , 659 , 660 , 662 , 663 , 668 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 60 ) , acute megakaryoblastic leukemia (M7) ( 60 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 60 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 60 ) , acute myeloblastic leukemia, without maturation (M1) ( 60 ) , chronic myelogenous leukemia ( 72 , 73 , 74 , 76 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 142 , 143 , 144 , 145 , 153 , 154 , 165 , 166 , 167 , 168 , 172 , 173 , 174 , 175 , 177 , 178 , 179 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 248 , 249 , 250 , 251 , 252 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 301 , 302 , 303 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 361 , 362 , 448 , 449 , 450 , 451 , 454 , 455 , 556 , 557 , 565 , 566 , 571 , 574 , 592 , 596 , 597 , 604 , 605 , 630 , 631 , 632 , 633 , 634 , 635 , 638 , 639 , 640 , 650 , 651 , 652 , 653 , 664 , 665 , 666 , 667 , 669 , 670 , 671 , 672 , 673 ) , T cell leukemia ( 83 ) , liver cancer ( 5 , 22 , 57 , 121 , 184 , 185 , 300 , 308 , 314 , 315 , 316 , 318 , 320 , 321 , 325 , 328 , 334 , 339 , 342 , 343 , 347 , 417 , 423 , 427 , 428 , 431 , 438 , 439 , 443 , 457 , 526 , 529 , 530 , 533 , 537 , 542 , 545 , 570 ) , liver adenocarcinoma ( 417 ) , cholangiocellular carcinoma ( 121 , 431 , 439 , 443 ) , cholangiocellular carcinoma, surrounding tissue ( 313 , 327 , 435 , 536 , 547 , 602 , 603 ) , hepatocellular carcinoma ( 22 , 308 , 314 , 315 , 316 , 318 , 320 , 321 , 325 , 328 , 334 , 339 , 342 , 343 , 347 , 423 , 427 , 428 , 438 , 526 , 529 , 530 , 533 , 537 , 542 , 545 , 570 ) , hepatocellular carcinoma, surrounding tissue ( 160 , 309 , 310 , 311 , 317 , 319 , 322 , 323 , 324 , 326 , 329 , 330 , 331 , 332 , 333 , 335 , 336 , 337 , 340 , 341 , 345 , 346 , 424 , 425 , 426 , 429 , 430 , 436 , 437 , 521 , 522 , 527 , 528 , 531 , 532 , 534 , 538 , 540 , 541 , 544 , 546 ) , liver cancer, surrounding tissue ( 183 , 186 , 187 , 188 , 338 , 344 , 525 , 539 ) , lung cancer ( 1 , 3 , 9 , 16 , 24 , 30 , 36 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 62 , 75 , 96 , 97 , 130 , 135 , 139 , 140 , 151 , 152 , 156 , 169 , 171 , 176 , 180 , 236 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 246 , 247 , 254 , 256 , 356 , 357 , 358 , 359 , 419 , 432 , 446 , 447 , 452 , 453 , 467 , 513 , 514 , 550 , 579 , 580 , 584 , 661 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 686 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 ) , non-small cell lung cancer ( 1 , 3 , 9 , 16 , 30 , 36 , 44 , 45 , 46 , 48 , 49 , 50 , 62 , 75 , 96 , 97 , 139 , 140 , 151 , 152 , 156 , 180 , 236 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 246 , 247 , 254 , 256 , 359 , 419 , 432 , 446 , 447 , 467 , 513 , 514 , 550 , 580 , 584 , 661 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 687 , 688 , 689 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 ) , non-small cell lung cancer, surrounding tissue ( 306 ) , non-small cell lung adenocarcinoma ( 1 , 3 , 24 , 30 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 96 , 97 , 139 , 140 , 236 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 246 , 247 , 254 , 256 , 446 , 447 , 513 , 514 , 550 , 661 ) , non-small cell lung adenocarcinoma, surrounding tissue ( 234 , 235 , 237 , 245 ) , non-small cell large cell lung carcinoma ( 1 , 9 , 16 , 45 , 48 ) , non-small cell squamous cell lung carcinoma ( 16 , 47 , 254 , 256 , 356 , 357 , 358 , 452 , 453 ) , non-small cell squamous cell lung carcinoma, surrounding tissue ( 515 ) , small-cell lung cancer ( 42 , 43 ) , lung cancer, surrounding tissue ( 101 , 102 , 103 , 104 , 105 , 106 , 170 ) , lymphoma ( 34 ) , B cell lymphoma ( 60 ) , Burkitt's lymphoma ( 34 ) , non-Hodgkin's lymphoma ( 60 ) , follicular lymphoma ( 34 ) , mantle cell lymphoma ( 34 ) , neuroblastoma ( 23 , 59 , 131 , 132 , 463 , 464 , 517 ) , ovarian cancer ( 18 , 27 , 32 , 136 , 161 , 162 , 164 , 189 , 190 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 ) , ovarian epithelial carcinoma ( 27 ) , pancreatic cancer ( 14 , 360 ) , pancreatic carcinoma ( 14 ) , pancreatic ductal adenocarcinoma ( 40 ) , multiple myeloma ( 60 , 414 , 415 ) , prostate cancer ( 25 , 191 ) , salivary gland cancer ( 461 ) , melanoma skin cancer ( 21 , 150 , 221 , 222 , 223 , 456 , 468 , 476 , 523 ) , leiomyosarcoma ( 63 ) , cancer, squamous cell carcinoma ( 19 ) , thymic carcinoma ( 98 ) , thyroid cancer, surrounding tissue ( 518 ) , ventricular tachycardia ( 99 , 100 , 108 , 109 , 110 ) , FTLD ( 124 ) , PAH ( 2 ) , hypersplenism ( 595 )
Relevant cell line - cell type - tissue:
'brain, cerebral cortex' ( 124 ) , 'heart, papillary muscle' ( 524 ) , 'liver, para-cholangiocellular carcinoma tissue' ( 121 ) , 'muscle, skeletal' ( 12 , 35 , 71 , 90 , 120 , 220 , 607 , 708 ) , 'muscle, skeletal' [SLC27A1 (human), transgenic] ( 39 ) , 'pancreatic, ductal'-pancreas ( 40 ) , 143.98.2 (bone cell) ( 637 ) , 23132/87 (gastric) ( 69 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 138 ) , 293 (epithelial) [AT1 (human), transfection] ( 134 ) , 293 (epithelial) ( 146 , 147 , 413 , 459 , 460 ) , 293E (epithelial) ( 95 ) , 44-ZW-5409 (eye cell) ( 646 ) , 786-O (renal) [VHL (human), transfection] ( 15 ) , 786-O (renal) ( 15 ) , A431 (epithelial) ( 715 ) , A498 (renal) ( 149 ) , A549 (pulmonary) [LKB1 (human), no information] ( 550 ) , A549 (pulmonary) ( 3 , 30 , 44 , 52 ) , AML-193 (monocyte) ( 60 ) , astrocyte [IDH1 (human), genetic knockin] ( 41 ) , BJAB (B lymphocyte) ( 34 ) , bone marrow ( 642 , 643 , 655 , 656 , 660 , 662 , 663 , 668 ) , breast ( 8 , 32 , 298 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 567 , 568 , 569 , 577 , 578 , 581 , 582 , 583 , 608 , 609 , 624 , 641 ) , BT-474 (breast cell) ( 13 ) , Cal-12T (pulmonary) ( 50 ) , Calu 6 (pulmonary) ( 1 , 62 ) , Calu-3 (pulmonary) ( 46 ) , cardiac-heart ( 108 , 109 ) , cholangiocyte-liver ( 431 , 439 , 443 ) , CL1-0 (pulmonary) ( 130 ) , CL1-1 (pulmonary) ( 130 ) , CL1-2 (pulmonary) ( 130 ) , CL1-5 (pulmonary) ( 130 ) , CMK (megakaryoblast) ( 60 ) , colon ( 126 , 127 , 129 , 155 , 416 , 418 , 420 , 421 , 441 , 442 , 444 , 445 , 549 , 551 , 552 , 553 , 554 , 686 ) , COS (fibroblast) ( 645 ) , CTS (myeloid) ( 60 ) , DG75 (B lymphocyte) ( 133 ) , DMS153 (pulmonary) ( 49 ) , DMS53 (pulmonary) ( 43 ) , DMS79 (pulmonary) ( 42 ) , DOHH2 ('B lymphocyte, precursor') ( 60 ) , DT14/06T (breast cell) ( 4 ) , EBC-1 (squamous) ( 16 ) , EOC ( 27 ) , esophagus ( 363 , 364 , 365 , 366 , 367 , 368 , 369 , 370 , 371 , 372 , 373 , 374 , 375 , 376 , 377 , 378 , 379 , 380 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 , 408 , 409 , 410 , 411 , 412 ) , FaDu (squamous) ( 19 ) , FL-18 (B lymphocyte) ( 34 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 64 ) , Flp-In T-Rex-293 (epithelial) ( 64 ) , FU97 (gastric) ( 181 , 182 ) , G-292 (bone cell) ( 636 ) , GM00130 (B lymphocyte) ( 148 ) , H2009 (pulmonary) ( 62 ) , H2077 (pulmonary) ( 62 ) , H2887 (pulmonary) ( 62 ) , H322M (pulmonary) ( 62 ) , HCC1359 (pulmonary) ( 62 ) , HCC15 (pulmonary) ( 47 ) , HCC2279 (pulmonary) ( 62 ) , HCC366 (pulmonary) ( 62 ) , HCC4006 (pulmonary) ( 62 ) , HCC44 (pulmonary) ( 50 ) , HCC78 (pulmonary) ( 48 , 62 ) , HCC827 (pulmonary) ( 46 , 62 , 139 , 140 , 661 ) , HCT116 (intestinal) ( 1 ) , heart ( 99 , 100 , 110 , 575 , 576 ) , HEK293T (epithelial) ( 20 ) , HEL (erythroid) ( 60 ) , HeLa (cervical) ( 5 , 6 , 16 , 29 , 56 , 205 , 422 , 458 , 520 , 555 , 593 ) , HeLa S3 (cervical) ( 192 , 519 ) , Hep 3B2.1-7 (hepatic) ( 22 ) , hepatic-'liver, para-cholangiocellular carcinoma tissue' ( 313 , 327 , 435 , 536 , 547 , 602 , 603 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 309 , 310 , 311 , 317 , 319 , 322 , 323 , 324 , 326 , 329 , 330 , 331 , 332 , 333 , 335 , 336 , 337 , 340 , 341 , 345 , 346 , 424 , 425 , 426 , 429 , 430 , 436 , 437 , 521 , 522 , 527 , 528 , 531 , 532 , 534 , 538 , 540 , 541 , 544 , 546 ) , hepatocyte-liver ( 5 , 160 , 308 , 314 , 315 , 316 , 318 , 320 , 321 , 325 , 328 , 334 , 339 , 342 , 343 , 347 , 423 , 427 , 428 , 438 , 526 , 529 , 530 , 533 , 537 , 542 , 545 , 570 ) , HepG2 (hepatic) ( 5 , 22 , 57 ) , HES-3 ('stem, embryonic') ( 122 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 33 ) , HMLER ('stem, breast cancer') ( 33 ) , HOP62 (pulmonary) ( 62 ) , HUES-9 ('stem, embryonic') ( 123 ) , Huh7 (hepatic) ( 22 ) , JEKO-1 (B lymphocyte) ( 34 ) , Jurkat (T lymphocyte) ( 53 , 68 , 84 , 85 , 86 , 87 , 88 , 89 , 91 , 92 , 93 , 94 , 107 , 125 , 128 , 157 , 158 , 159 , 163 , 270 , 288 , 289 , 305 , 312 , 391 , 440 , 465 , 466 , 469 , 470 , 471 , 472 , 473 , 474 , 475 , 477 , 516 , 535 , 543 , 548 , 610 , 649 , 710 ) , Jurkat E6-1 (T lymphocyte) ( 58 ) , K562 (erythroid) ( 56 , 72 , 73 , 74 , 76 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 142 , 143 , 144 , 145 , 153 , 154 , 165 , 166 , 167 , 168 , 172 , 173 , 174 , 175 , 177 , 178 , 179 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 214 , 215 , 216 , 217 , 218 , 219 , 224 , 225 , 226 , 227 , 228 , 229 , 230 , 231 , 232 , 233 , 248 , 249 , 250 , 251 , 252 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 301 , 302 , 303 , 348 , 349 , 350 , 351 , 352 , 353 , 354 , 355 , 361 , 362 , 448 , 449 , 450 , 451 , 454 , 455 , 556 , 557 , 565 , 566 , 571 , 574 , 592 , 596 , 597 , 604 , 605 , 630 , 631 , 632 , 633 , 634 , 635 , 638 , 639 , 640 , 650 , 651 , 652 , 653 , 654 , 664 , 665 , 666 , 667 , 669 , 670 , 671 , 672 , 673 ) , Kasumi-1 (myeloid) ( 60 ) , KATO III (gastric) ( 253 , 258 ) , KG-1 (myeloid) ( 60 , 70 ) , KG-1a (myeloid) ( 75 ) , kidney ( 299 , 304 , 307 ) , Kit225 (T lymphocyte) ( 83 ) , LAN-6 (neural crest) ( 23 , 463 , 464 ) , LCLC-103H (pulmonary) ( 62 ) , liver ( 38 , 121 , 183 , 184 , 185 , 186 , 187 , 188 , 300 , 338 , 344 , 525 , 539 ) , LNCaP (prostate cell) ( 191 ) , LOU-NH91 (squamous) ( 47 , 62 ) , lung ( 2 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 96 , 97 , 101 , 102 , 103 , 104 , 105 , 106 , 135 , 151 , 152 , 156 , 169 , 170 , 171 , 176 , 180 , 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 306 , 356 , 357 , 358 , 359 , 419 , 446 , 447 , 452 , 453 , 513 , 514 , 515 , 579 , 580 , 584 , 674 , 675 , 676 , 677 , 678 , 679 , 680 , 681 , 682 , 683 , 684 , 685 , 687 , 688 , 689 , 690 , 691 , 692 , 693 , 694 , 695 , 696 , 697 , 698 , 699 , 700 , 701 , 702 , 703 , 704 , 705 , 706 , 707 ) , MCF-7 (breast cell) ( 13 ) , MDA-MB-436 (breast cell) ( 10 ) , melanocyte-skin ( 55 ) , MIA PaCa-2 (pancreatic) ( 14 ) , MKN-45 (gastric) ( 255 , 257 ) , MTH52C (breast cell) ( 4 ) , MTH53A (breast cell) ( 4 ) , MV4-11 (macrophage) ( 60 , 659 ) , NB10 (neural crest) ( 59 ) , NCEB-1 (B lymphocyte) ( 34 ) , NCI-H128 (pulmonary) ( 42 ) , NCI-H1299 (pulmonary) ( 3 , 36 , 45 , 75 ) , NCI-H1355 (pulmonary) ( 44 ) , NCI-H1395 (pulmonary) ( 62 ) , NCI-H1417 (pulmonary) ( 42 ) , NCI-H1437 (pulmonary) ( 49 , 50 ) , NCI-H1568 (pulmonary) ( 62 ) , NCI-H157 (pulmonary) ( 62 ) , NCI-H1648 (pulmonary) ( 62 ) , NCI-H1650 (pulmonary) ( 46 ) , NCI-H1666 (pulmonary) ( 50 , 62 ) , NCI-H1703 (squamous) ( 47 , 254 , 256 ) , NCI-H1734 (pulmonary) ( 45 ) , NCI-H1781 (pulmonary) ( 48 ) , NCI-H1792 (pulmonary) [LKB1 (human), no information] ( 432 ) , NCI-H1792 (pulmonary) ( 44 , 433 , 434 ) , NCI-H1944 (pulmonary) ( 45 ) , NCI-H1975 (pulmonary) ( 46 ) , NCI-H2030 (pulmonary) ( 62 ) , NCI-H2073 (pulmonary) ( 47 , 49 ) , NCI-H209 (pulmonary) ( 42 , 49 ) , NCI-H2106 (pulmonary) ( 46 ) , NCI-H2172 (pulmonary) ( 62 ) , NCI-H2228 (pulmonary) ( 48 ) , NCI-H23 (pulmonary) ( 44 ) , NCI-H2342 (pulmonary) ( 47 ) , NCI-H2405 (pulmonary) ( 50 ) , NCI-H3122 (pulmonary) ( 48 ) , NCI-H322 (pulmonary) ( 62 ) , NCI-H358 (pulmonary) ( 45 , 467 ) , NCI-H441 (pulmonary) ( 44 ) , NCI-H446 (pulmonary) ( 43 ) , NCI-H460 (pulmonary) ( 1 , 9 , 16 , 45 , 62 ) , NCI-H520 (squamous) ( 62 ) , NCI-H524 (pulmonary) ( 42 ) , NCI-H526 (pulmonary) ( 43 ) , NCI-H647 (pulmonary) ( 62 ) , NCI-H661 (pulmonary) ( 48 ) , NCI-H69 (pulmonary) ( 43 ) , NCI-H82 (pulmonary) ( 43 ) , NCI-H838 (pulmonary) ( 49 ) , NCI-H929 (B lymphocyte) ( 414 ) , NHDF (fibroblast) ( 55 ) , NOMO-1 (myeloid) ( 657 , 658 ) , NPC (neural crest) ( 59 ) , OCI-ly1 (B lymphocyte) ( 34 ) , OPM-2 (plasma cell) ( 60 ) , OV202 (ovarian) ( 18 ) , ovary ( 32 , 161 , 162 , 164 , 189 , 190 , 613 , 614 , 615 , 616 , 617 , 618 , 619 , 620 , 621 , 622 , 623 ) , P31/FUJ (erythroid) ( 60 ) , pancreas ( 360 ) , PC3 (prostate cell) ( 25 ) , PC9 (pulmonary) ( 24 , 62 ) , platelet-blood ( 606 ) , Raji (B lymphocyte) ( 34 ) , RAMOS (B lymphocyte) ( 34 ) , REC-1 (B lymphocyte) ( 34 ) , RL ('B lymphocyte, precursor') ( 60 ) , RPMI-8266 (plasma cell) ( 60 ) , salivary gland ( 461 , 462 ) , SH-SY5Y (neural crest) ( 23 , 37 , 131 , 132 ) , SK-HEP-1 (endothelial) ( 417 ) , SK-LMS-1 (muscle cell) ( 63 ) , SKBr3 (breast cell) ( 61 ) , skin ( 150 , 221 , 222 , 223 , 456 , 468 , 476 , 523 ) , SMS-KCN (neural crest) ( 23 , 517 ) , SMS-KCN-A (neural crest) ( 23 ) , SNU-398 (hepatic) ( 457 ) , spleen ( 595 ) , stomach ( 268 , 269 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 281 , 282 , 283 , 284 , 285 , 286 , 287 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 487 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 495 , 496 , 497 , 498 , 499 , 500 , 501 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 510 , 511 , 512 , 572 , 573 , 585 , 586 , 587 , 588 , 589 , 590 , 591 , 594 , 598 , 599 , 600 , 601 ) , SU-DHL-4 (B lymphocyte) ( 34 ) , SU-DHL-6 (B lymphocyte) ( 60 ) , Su.86.86 (pancreatic) ( 14 ) , SW480 (intestinal) ( 17 , 611 , 612 ) , SW620 (intestinal) ( 17 ) , thymus ( 98 ) , thyroid ( 518 ) , TOV21G (ovarian) ( 18 ) , TYK-nu (ovarian) ( 136 ) , U-251 MG (glial) ( 19 ) , U266 (plasma cell) ( 60 , 415 ) , U2OS (bone cell) [GR (human)] ( 647 ) , U87MG (glial) ( 11 ) , UPN-1 (B lymphocyte) ( 34 ) , WM239A (melanocyte) ( 21 ) , ZMTH3 (breast cell) ( 4 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 19 ) , BRAF (human) ( 55 ) , IDH1 (human) ( 41 ) , Myc (human) ( 30 ) , PDHK1 (human) ( 75 ) , PDHK4 (human) ( 1 , 3 ) , PDK1 (human) ( 17 ) , SULF1 (human) ( 18 )
Putative in vivo kinases:
PDK1 (human) ( 55 )
Kinases, in vitro:
PDHK1 (human) ( 709 , 711 , 713 , 714 ) , PDHK2 (human) ( 709 , 711 , 712 , 713 ) , PDHK3 (human) ( 709 , 711 , 712 ) , PDHK4 (human) ( 478 , 709 , 711 , 712 ) , PDK1 (human) ( 712 )
Putative upstream phosphatases:
PDP2 (human) ( 55 )
Phosphatases, in vitro:
PDP1 (human) ( 36 , 714 )
Treatments:
1,25_dihydroxyvitamin_D ( 12 ) , apitolisib ( 19 ) , AZD7545 ( 1 ) , butyrate ( 5 ) , CoCL2 ( 57 ) , CT-99021 ( 17 ) , dactolisib ( 19 ) , DCA ( 2 , 4 , 5 , 19 , 75 ) , DMOG ( 57 ) , doxycycline ( 19 ) , EGF ( 6 , 28 , 36 ) , exercise ( 90 , 607 , 708 ) , fasting ( 35 ) , GH ( 35 ) , glucose_starvation ( 10 ) , HH-F3 ( 22 ) , high-fat diet ( 39 ) , high_glucose ( 10 ) , hypoxia ( 14 , 57 ) , JX06 ( 16 ) , lncRNAs ( 17 ) , metastatic potential ( 130 ) , miRNA ( 3 ) , MK-2206 ( 19 ) , monolayer culture ( 9 ) , nicotinamide ( 5 ) , nocodazole ( 192 ) , normal chow diet ( 39 ) , siRNA ( 55 ) , spheroid culture ( 9 ) , taselisib ( 19 ) , terbutaline ( 26 ) , TK1258 ( 75 ) , trichostatin_A ( 5 ) , U0126 ( 58 ) , VER-246608 ( 25 )

Downstream Regulation
Effects of modification on PDHA1:
activity, induced ( 708 ) , activity, inhibited ( 27 ) , enzymatic activity, inhibited ( 25 , 41 , 644 , 713 , 714 )
Effects of modification on biological processes:
cell growth, induced ( 14 )

Disease / Diagnostics Relevance
Relevant diseases:
PAH ( 2 )

References 

1

Trinidad AG, et al. (2017) Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumour cells. Oncogene 36, 6164-6176
28692044   Curated Info

2

Michelakis ED, et al. (2017) Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Sci Transl Med 9
29070699   Curated Info

3

Li G, et al. (2017) The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis. Oncogene 36, 989-998
27641336   Curated Info

4

Harting TP, et al. (2017) Dichloroacetate affects proliferation but not apoptosis in canine mammary cell lines. PLoS One 12, e0178744
28591165   Curated Info

5

Xu S, et al. (2017) Butyrate induces apoptosis by activating PDC and inhibiting complex I through SIRT3 inactivation. Signal Transduct Target Ther 2, 16035
29263907   Curated Info

6

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

7

Zhao H, Pflug BR, Lai X, Wang M (2016) Pyruvate dehydrogenase alpha 1 as a target of omega-3 polyunsaturated fatty acids in human prostate cancer through a global phosphoproteomic analysis. Proteomics 16, 2419-31
27357730   Curated Info

8

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

9

Jiang L, et al. (2016) Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature 532, 255-8
27049945   Curated Info

10

Park S, et al. (2016) ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer. Cell Rep 15, 323-35
27050525   Curated Info

11

Li X, et al. (2016) Mitochondria-Translocated PGK1 Functions as a Protein Kinase to Coordinate Glycolysis and the TCA Cycle in Tumorigenesis. Mol Cell 61, 705-19
26942675   Curated Info

12

Ryan ZC, et al. (2016) 1α,25-Dihydroxyvitamin D3 Regulates Mitochondrial Oxygen Consumption and Dynamics in Human Skeletal Muscle Cells. J Biol Chem 291, 1514-28
26601949   Curated Info

13

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

14

Golias T, et al. (2016) Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. Sci Rep 6, 31146
27498883   Curated Info

15

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

16

Sun W, et al. (2015) JX06 Selectively Inhibits Pyruvate Dehydrogenase Kinase PDK1 by a Covalent Cysteine Modification. Cancer Res 75, 4923-36
26483203   Curated Info

17

Wang J, et al. (2015) miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells. Oncotarget 6, 37852-70
26497997   Curated Info

18

Mondal S, et al. (2015) HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget 6, 33705-19
26378042   Curated Info

19

Cerniglia GJ, et al. (2015) The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation. Mol Cancer Ther 14, 1928-38
25995437   Curated Info

20

Franchin C, et al. (2015) Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells. Biochim Biophys Acta 1854, 609-23
25278378   Curated Info

21

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

22

Jhuang HJ, et al. (2015) Gluconeogenesis, lipogenesis, and HBV replication are commonly regulated by PGC-1α-dependent pathway. Oncotarget 6, 7788-803
25762623   Curated Info

23

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

24

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

25

Moore JD, et al. (2014) VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget 5, 12862-76
25404640   Curated Info

26

Kalsen A, et al. (2014) Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance. J Appl Physiol (1985) 117, 1180-7
25257871   Curated Info

27

Alvero AB, et al. (2014) Multiple blocks in the engagement of oxidative phosphorylation in putative ovarian cancer stem cells: implication for maintenance therapy with glycolysis inhibitors. Oncotarget 5, 8703-15
25237928   Curated Info

28

Fan J, et al. (2014) Tyr-301 phosphorylation inhibits pyruvate dehydrogenase by blocking substrate binding and promotes the Warburg effect. J Biol Chem 289, 26533-41
25104357   Curated Info

29

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

30

Edmunds LR, et al. (2014) c-Myc Programs Fatty Acid Metabolism and Dictates Acetyl-CoA Abundance and Fate. J Biol Chem 289, 25382-92
25053415   Curated Info

31

Sutendra G, et al. (2014) A Nuclear Pyruvate Dehydrogenase Complex Is Important for the Generation of Acetyl-CoA and Histone Acetylation. Cell 158, 84-97
24995980   Curated Info

32

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

33

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

34

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

35

Nellemann B, et al. (2014) Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol (Oxf) 210, 392-402
24148194   Curated Info

36

Fan J, et al. (2014) Tyr Phosphorylation of PDP1 Toggles Recruitment between ACAT1 and SIRT3 to Regulate the Pyruvate Dehydrogenase Complex. Mol Cell 53, 534-48
24486017   Curated Info

37

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

38

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

39

Guitart M, et al. (2014) Fatty Acid Transport Protein 1 (FATP1) Localizes in Mitochondria in Mouse Skeletal Muscle and Regulates Lipid and Ketone Body Disposal. PLoS One 9, e98109
24858472   Curated Info

40

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

41

Izquierdo-Garcia JL, et al. (2014) Glioma Cells with the IDH1 Mutation Modulate Metabolic Fractional Flux through Pyruvate Carboxylase. PLoS One 9, e108289
25243911   Curated Info

42

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

43

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

44

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

45

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

46

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

47

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

48

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

49

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

50

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

51

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

52

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

53

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

54

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

55

Kaplon J, et al. (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109-12
23685455   Curated Info

56

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

57

Borcar A, Menze MA, Toner M, Hand SC (2013) Metabolic preconditioning of mammalian cells: mimetic agents for hypoxia lack fidelity in promoting phosphorylation of pyruvate dehydrogenase. Cell Tissue Res 351, 99-106
23138570   Curated Info

58

Helou YA, Nguyen V, Beik SP, Salomon AR (2013) ERK positive feedback regulates a widespread network of tyrosine phosphorylation sites across canonical T cell signaling and actin cytoskeletal proteins in Jurkat T cells. PLoS One 8, e69641
23874979   Curated Info

59

DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513
24349301   Curated Info

60

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

61

Imami K, et al. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways. Mol Cell Proteomics 11, 1741-57
22964224   Curated Info

62

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

63

Bai Y, et al. (2012) Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors. Cancer Res 72, 2501-11
22461510   Curated Info

64

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

65

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

66

Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

67

Xue X, et al. (2012) Mitaplatin increases sensitivity of tumor cells to Cisplatin by inducing mitochondrial dysfunction. Mol Pharm 9, 634-44
22289032   Curated Info

68

Mulhern D (2012) CST Curation Set: 13827; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

69

Tucker M (2012) CST Curation Set: 13494; Year: 2012; Biosample/Treatment: cell line, 23132/87/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

70

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

71

Lundby A, et al. (2012) Quantitative maps of protein phosphorylation sites across 14 different rat organs and tissues. Nat Commun 3, 876
22673903   Curated Info

72

Zhou J (2011) CST Curation Set: 12806; Year: 2011; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Zhou J (2011) CST Curation Set: 12808; Year: 2011; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

74

Zhou J (2011) CST Curation Set: 12810; Year: 2011; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

75

Hitosugi T, et al. (2011) Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell 44, 864-77
22195962   Curated Info

76

Mulhern D (2011) CST Curation Set: 13266; Year: 2011; Biosample/Treatment: cell line, K-562/untreated &'||' untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

77

Rikova K (2011) CST Curation Set: 13116; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

78

Rikova K (2011) CST Curation Set: 13118; Year: 2011; Biosample/Treatment: cell line, MGH-6/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

79

Rikova K (2011) CST Curation Set: 13120; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

80

Rikova K (2011) CST Curation Set: 13122; Year: 2011; Biosample/Treatment: cell line, MGH-10/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

81

Rikova K (2011) CST Curation Set: 13126; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

82

Rikova K (2011) CST Curation Set: 13130; Year: 2011; Biosample/Treatment: cell line, MGH-8/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

83

Osinalde N, et al. (2011) Interleukin-2 signaling pathway analysis by quantitative phosphoproteomics. J Proteomics 75, 177-91
21722762   Curated Info

84

Mulhern D (2011) CST Curation Set: 12686; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

85

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

86

Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

87

Mulhern D (2011) CST Curation Set: 12681; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

88

Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

89

Mulhern D (2011) CST Curation Set: 12644; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Kiilerich K, et al. (2011) Exercise-induced pyruvate dehydrogenase activation is not affected by 7 days of bed rest. J Appl Physiol 111, 751-7
21680880   Curated Info

91

Zhou J (2011) CST Curation Set: 12347; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

92

Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

93

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

94

Guo A (2011) CST Curation Set: 12063; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

95

Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22
21659604   Curated Info

96

Ren H (2011) CST Curation Set: 11775; Year: 2011; Biosample/Treatment: cell line, RP92/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Ren H (2011) CST Curation Set: 11784; Year: 2011; Biosample/Treatment: cell line, RP101/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Li Y (2011) CST Curation Set: 10458; Year: 2011; Biosample/Treatment: tissue, thymus/untreated; Disease: thymic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Li Y (2011) CST Curation Set: 10523; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Li Y (2011) CST Curation Set: 10524; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

101

Tucker M (2011) CST Curation Set: 10943; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Tucker M (2011) CST Curation Set: 10945; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Tucker M (2011) CST Curation Set: 10947; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Tucker M (2011) CST Curation Set: 10949; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Tucker M (2011) CST Curation Set: 10951; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Tucker M (2011) CST Curation Set: 10953; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Tucker M (2011) CST Curation Set: 10954; Year: 2011; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Li Y (2011) CST Curation Set: 10453; Year: 2011; Biosample/Treatment: heart, cardiac/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

109

Li Y (2011) CST Curation Set: 10435; Year: 2011; Biosample/Treatment: heart, cardiac/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Li Y (2011) CST Curation Set: 10436; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

111

Moritz A (2011) CST Curation Set: 11304; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

112

Moritz A (2011) CST Curation Set: 11305; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Moritz A (2011) CST Curation Set: 11306; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Moritz A (2011) CST Curation Set: 11307; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Moritz A (2011) CST Curation Set: 11308; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Moritz A (2011) CST Curation Set: 11309; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Moritz A (2011) CST Curation Set: 11310; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Moritz A (2011) CST Curation Set: 11311; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Moritz A (2011) CST Curation Set: 11312; Year: 2011; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

120

Zhao X, et al. (2011) Phosphoproteome analysis of functional mitochondria isolated from resting human muscle reveals extensive phosphorylation of inner membrane protein complexes and enzymes. Mol Cell Proteomics 10, M110.000299
20833797   Curated Info

121

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

122

Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538
21437283   Curated Info

123

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

124

Herskowitz JH, et al. (2010) Phosphoproteomic Analysis Reveals Site-Specific Changes in GFAP and NDRG2 Phosphorylation in Frontotemporal Lobar Degeneration. J Proteome Res 9, 6368-79
20886841   Curated Info

125

Possemato A (2010) CST Curation Set: 10867; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

126

Tucker M (2010) CST Curation Set: 10847; Year: 2010; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

127

Tucker M (2010) CST Curation Set: 10857; Year: 2010; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

128

Possemato A (2010) CST Curation Set: 10868; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

129

Tucker M (2010) CST Curation Set: 10849; Year: 2010; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

130

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

131

Guo A (2010) CST Curation Set: 10556; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Guo A (2010) CST Curation Set: 10557; Year: 2010; Biosample/Treatment: cell line, SH-SY5Y/NGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

133

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

134

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

135

Tucker M (2010) CST Curation Set: 10313; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

136

Tucker M (2010) CST Curation Set: 10086; Year: 2010; Biosample/Treatment: cell line, TYK-nu/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

137

Rikova K (2010) CST Curation Set: 10045; Year: 2010; Biosample/Treatment: cell line, DFCI ERC17 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

138

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

139

Rikova K (2010) CST Curation Set: 10028; Year: 2010; Biosample/Treatment: cell line, HCC827/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

140

Rikova K (2010) CST Curation Set: 10031; Year: 2010; Biosample/Treatment: cell line, HCC827/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

141

Rikova K (2010) CST Curation Set: 10033; Year: 2010; Biosample/Treatment: cell line, DFCI HCC827 triple/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

142

Moritz A (2010) CST Curation Set: 10027; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

143

Moritz A (2010) CST Curation Set: 10026; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

144

Moritz A (2010) CST Curation Set: 10025; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

145

Moritz A (2010) CST Curation Set: 10024; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

146

Guo A (2010) CST Curation Set: 6258; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

147

Guo A (2010) CST Curation Set: 6259; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) Phe Antibody Cat#: 9631
Curated Info

148

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

149

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

150

Tucker M (2010) CST Curation Set: 9781; Year: 2010; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

151

Rikova K (2010) CST Curation Set: 9761; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

152

Rikova K (2010) CST Curation Set: 9772; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

153

Moritz A (2010) CST Curation Set: 9707; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

154

Moritz A (2010) CST Curation Set: 9709; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

155

Tucker M (2010) CST Curation Set: 9502; Year: 2010; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

156

Rikova K (2010) CST Curation Set: 9466; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

157

Possemato A (2010) CST Curation Set: 9290; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

158

Possemato A (2010) CST Curation Set: 9289; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

159

Possemato A (2010) CST Curation Set: 9292; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

160

Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9
20166139   Curated Info

161

Ren H (2010) CST Curation Set: 8821; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

162

Ren H (2010) CST Curation Set: 8825; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

163

Possemato A (2010) CST Curation Set: 8973; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

164

Ren H (2010) CST Curation Set: 8811; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

165

Possemato A (2010) CST Curation Set: 8938; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

166

Possemato A (2010) CST Curation Set: 8944; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

167

Possemato A (2010) CST Curation Set: 8941; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

168

Possemato A (2010) CST Curation Set: 8939; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

169

Hu Y (2010) CST Curation Set: 8712; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

170

Hu Y (2010) CST Curation Set: 8707; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

171

Hu Y (2010) CST Curation Set: 8708; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

172

Possemato A (2010) CST Curation Set: 8936; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

173

Possemato A (2010) CST Curation Set: 8942; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

174

Possemato A (2010) CST Curation Set: 8937; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

175

Moritz A (2010) CST Curation Set: 8835; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

176

Hu Y (2010) CST Curation Set: 8945; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

177

Moritz A (2010) CST Curation Set: 8836; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

178

Moritz A (2010) CST Curation Set: 8833; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

179

Moritz A (2010) CST Curation Set: 8834; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

180

Rikova K (2010) CST Curation Set: 9124; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

181

Ren H (2010) CST Curation Set: 9100; Year: 2010; Biosample/Treatment: cell line, FU97/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

182

Ren H (2010) CST Curation Set: 9101; Year: 2010; Biosample/Treatment: cell line, FU97/Gleevec; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

183

Tucker M (2010) CST Curation Set: 8913; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

184

Tucker M (2010) CST Curation Set: 8910; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

185

Tucker M (2010) CST Curation Set: 8914; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

186

Tucker M (2010) CST Curation Set: 8911; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

187

Tucker M (2010) CST Curation Set: 8909; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

188

Tucker M (2010) CST Curation Set: 8915; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

189

Ren H (2010) CST Curation Set: 8889; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

190

Ren H (2010) CST Curation Set: 8893; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

191

Chen L, Giorgianni F, Beranova-Giorgianni S (2010) Characterization of the phosphoproteome in LNCaP prostate cancer cells by in-gel isoelectric focusing and tandem mass spectrometry. J Proteome Res 9, 174-8
20044836   Curated Info

192

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

193

Moritz A (2009) CST Curation Set: 8716; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

194

Moritz A (2009) CST Curation Set: 8717; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

195

Moritz A (2009) CST Curation Set: 8715; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

196

Moritz A (2009) CST Curation Set: 8718; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

197

Possemato A (2009) CST Curation Set: 8671; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

198

Moritz A (2009) CST Curation Set: 8616; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

199

Moritz A (2009) CST Curation Set: 8617; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

200

Moritz A (2009) CST Curation Set: 8618; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

201

Moritz A (2009) CST Curation Set: 8619; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

202

Moritz A (2009) CST Curation Set: 8620; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

203

Moritz A (2009) CST Curation Set: 8621; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

204

Moritz A (2009) CST Curation Set: 8622; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

205

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

206

Moritz A (2009) CST Curation Set: 8608; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

207

Moritz A (2009) CST Curation Set: 8609; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

208

Moritz A (2009) CST Curation Set: 8611; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

209

Moritz A (2009) CST Curation Set: 8612; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

210

Moritz A (2009) CST Curation Set: 8613; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

211

Moritz A (2009) CST Curation Set: 8614; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

212

Moritz A (2009) CST Curation Set: 8615; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

213

Moritz A (2009) CST Curation Set: 8521; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

214

Moritz A (2009) CST Curation Set: 8522; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

215

Moritz A (2009) CST Curation Set: 8527; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

216

Moritz A (2009) CST Curation Set: 8524; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

217

Moritz A (2009) CST Curation Set: 8525; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

218

Moritz A (2009) CST Curation Set: 8518; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

219

Moritz A (2009) CST Curation Set: 8520; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

220

Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65
19764811   Curated Info

221

Tucker M (2009) CST Curation Set: 8384; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

222

Tucker M (2009) CST Curation Set: 8380; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

223

Tucker M (2009) CST Curation Set: 8376; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

224

Moritz A (2009) CST Curation Set: 8495; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

225

Moritz A (2009) CST Curation Set: 8494; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

226

Moritz A (2009) CST Curation Set: 8499; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

227

Moritz A (2009) CST Curation Set: 8500; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

228

Moritz A (2009) CST Curation Set: 8497; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

229

Moritz A (2009) CST Curation Set: 8498; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

230

Moritz A (2009) CST Curation Set: 8492; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

231

Moritz A (2009) CST Curation Set: 8490; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

232

Moritz A (2009) CST Curation Set: 8489; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

233

Moritz A (2009) CST Curation Set: 8491; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

234

Ren H (2009) CST Curation Set: 8199; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

235

Ren H (2009) CST Curation Set: 8195; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

236

Ren H (2009) CST Curation Set: 8202; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

237

Ren H (2009) CST Curation Set: 8321; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

238

Ren H (2009) CST Curation Set: 8328; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

239

Ren H (2009) CST Curation Set: 8323; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

240

Ren H (2009) CST Curation Set: 8185; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

241

Ren H (2009) CST Curation Set: 8183; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

242

Ren H (2009) CST Curation Set: 8186; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

243

Ren H (2009) CST Curation Set: 8182; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

244

Ren H (2009) CST Curation Set: 8102; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

245

Ren H (2009) CST Curation Set: 8101; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

246

Ren H (2009) CST Curation Set: 8103; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

247

Ren H (2009) CST Curation Set: 8104; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

248

Moritz A (2009) CST Curation Set: 8419; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

249

Moritz A (2009) CST Curation Set: 8425; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

250

Moritz A (2009) CST Curation Set: 8426; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

251

Moritz A (2009) CST Curation Set: 8427; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

252

Moritz A (2009) CST Curation Set: 8428; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

253

Possemato A (2009) CST Curation Set: 8414; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

254

Possemato A (2009) CST Curation Set: 8409; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

255

Possemato A (2009) CST Curation Set: 8412; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

256

Possemato A (2009) CST Curation Set: 8410; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

257

Possemato A (2009) CST Curation Set: 8411; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

258

Possemato A (2009) CST Curation Set: 8413; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

259

Moritz A (2009) CST Curation Set: 8421; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

260

Moritz A (2009) CST Curation Set: 8420; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

261

Moritz A (2009) CST Curation Set: 8422; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

262

Moritz A (2009) CST Curation Set: 8423; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

263

Moritz A (2009) CST Curation Set: 8424; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

264

Moritz A (2009) CST Curation Set: 8209; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

265

Moritz A (2009) CST Curation Set: 8206; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

266

Moritz A (2009) CST Curation Set: 8207; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

267

Moritz A (2009) CST Curation Set: 8208; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

268

Ren H (2009) CST Curation Set: 8058; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

269

Ren H (2009) CST Curation Set: 8060; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

270

Possemato A (2009) CST Curation Set: 8203; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

271

Ren H (2009) CST Curation Set: 8029; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

272

Ren H (2009) CST Curation Set: 8054; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

273

Ren H (2009) CST Curation Set: 8052; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

274

Ren H (2009) CST Curation Set: 8099; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

275

Ren H (2009) CST Curation Set: 8053; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

276

Ren H (2009) CST Curation Set: 8057; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

277

Ren H (2009) CST Curation Set: 8100; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

278

Ren H (2009) CST Curation Set: 8030; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

279

Ren H (2009) CST Curation Set: 8028; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

280

Ren H (2009) CST Curation Set: 8023; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

281

Ren H (2009) CST Curation Set: 8021; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

282

Ren H (2009) CST Curation Set: 8024; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

283

Ren H (2009) CST Curation Set: 8017; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

284

Ren H (2009) CST Curation Set: 8015; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

285

Ren H (2009) CST Curation Set: 8016; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

286

Ren H (2009) CST Curation Set: 8018; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

287

Ren H (2009) CST Curation Set: 8019; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

288

Possemato A (2009) CST Curation Set: 8192; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

289

Possemato A (2009) CST Curation Set: 8188; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

290

Moritz A (2009) CST Curation Set: 8095; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

291

Moritz A (2009) CST Curation Set: 8096; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

292

Moritz A (2009) CST Curation Set: 8097; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

293

Moritz A (2009) CST Curation Set: 8098; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

294

Moritz A (2009) CST Curation Set: 8031; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

295

Moritz A (2009) CST Curation Set: 8032; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

296

Moritz A (2009) CST Curation Set: 8033; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

297

Moritz A (2009) CST Curation Set: 8034; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

298

Tucker M (2009) CST Curation Set: 7968; Year: 2009; Biosample/Treatment: tissue, breast/untreated; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

299

Tucker M (2009) CST Curation Set: 7704; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

300

Tucker M (2009) CST Curation Set: 7753; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

301

Moritz A (2009) CST Curation Set: 8008; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

302

Moritz A (2009) CST Curation Set: 8009; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

303

Moritz A (2009) CST Curation Set: 8010; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

304

Tucker M (2009) CST Curation Set: 7694; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

305

Possemato A (2009) CST Curation Set: 7860; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

306

Rikova K (2009) CST Curation Set: 7627; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

307

Tucker M (2009) CST Curation Set: 7686; Year: 2009; Biosample/Treatment: tissue, kidney/untreated; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

308

Gu T (2009) CST Curation Set: 7733; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

309

Gu T (2009) CST Curation Set: 7734; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

310

Gu T (2009) CST Curation Set: 7732; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

311

Tucker M (2009) CST Curation Set: 7808; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

312

Possemato A (2009) CST Curation Set: 7811; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

313

Gu T (2009) CST Curation Set: 7587; Year: 2009; Biosample/Treatment: liver, para-cholangiocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

314

Gu T (2009) CST Curation Set: 7583; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

315

Gu T (2009) CST Curation Set: 7585; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

316

Gu T (2009) CST Curation Set: 7584; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

317

Gu T (2009) CST Curation Set: 7579; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

318

Gu T (2009) CST Curation Set: 7580; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

319

Gu T (2009) CST Curation Set: 7573; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

320

Gu T (2009) CST Curation Set: 7568; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

321

Gu T (2009) CST Curation Set: 7574; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

322

Gu T (2009) CST Curation Set: 7571; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

323

Gu T (2009) CST Curation Set: 7567; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

324

Gu T (2009) CST Curation Set: 7563; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

325

Gu T (2009) CST Curation Set: 7560; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

326

Gu T (2009) CST Curation Set: 7555; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

327

Gu T (2009) CST Curation Set: 7557; Year: 2009; Biosample/Treatment: liver, para-cholangiocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

328

Gu T (2009) CST Curation Set: 7550; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

329

Gu T (2009) CST Curation Set: 7543; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

330

Gu T (2009) CST Curation Set: 7541; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

331

Gu T (2009) CST Curation Set: 7547; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

332

Gu T (2009) CST Curation Set: 7549; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

333

Gu T (2009) CST Curation Set: 7545; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

334

Gu T (2009) CST Curation Set: 7536; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

335

Gu T (2009) CST Curation Set: 7533; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

336

Gu T (2009) CST Curation Set: 7539; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

337

Gu T (2009) CST Curation Set: 7535; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

338

Gu T (2009) CST Curation Set: 7531; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

339

Gu T (2009) CST Curation Set: 7538; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

340

Gu T (2009) CST Curation Set: 7537; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

341

Gu T (2009) CST Curation Set: 7523; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

342

Gu T (2009) CST Curation Set: 7524; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

343

Gu T (2009) CST Curation Set: 7528; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

344

Gu T (2009) CST Curation Set: 7525; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

345

Gu T (2009) CST Curation Set: 7527; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

346

Gu T (2009) CST Curation Set: 7521; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

347

Gu T (2009) CST Curation Set: 7522; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

348

Possemato A (2009) CST Curation Set: 7454; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

349

Possemato A (2009) CST Curation Set: 7452; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

350

Possemato A (2009) CST Curation Set: 7453; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

351

Possemato A (2009) CST Curation Set: 7355; Year: 2009; Biosample/Treatment: cell line, K562/Gleevec; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

352

Possemato A (2009) CST Curation Set: 7360; Year: 2009; Biosample/Treatment: cell line, K562/control; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

353

Possemato A (2009) CST Curation Set: 7357; Year: 2009; Biosample/Treatment: cell line, K562/Gleevec; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

354